Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will host a conference call at 8:30 a.m. E.T. on August 13, 2024, to provide a business update and discuss financial results.
Tuesday, August 13, 8:30 a.m. E.T.
Domestic: (877) 405-1242
International: (201) 389-0852
Webcast Registration: Click Here
An archived version of the call will be available approximately two hours after the completion of the event on the Marinus website at ir.marinuspharma.com/events-and-presentations.
About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company first introduced FDA-approved prescription medication ZTALMY® (ganaxolone) oral suspension CV in the U.S. in 2022. For more information about Marinus visit www.marinuspharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730576206/en/
Marinus Pharmaceuticals Inc. Stock
Our community is currently high on Marinus Pharmaceuticals Inc. with 3 Buy predictions and 0 Sell predictions.
Based on the current price of 1.25 € the target price of 4 € shows a potential of 220.0% for Marinus Pharmaceuticals Inc. which would more than double the current price.
